The 62nd American Society of Hematology Annual Meeting and Exposition ASH 2020
![The 62nd American Society of Hematology Annual Meeting and Exposition ASH 2020](/images/conferences/the-62nd-american-society-of-hematology-annual-meeting-and-exposition-ash-2020_big.jpeg)
Programme du congrès
Lieu : San Diego
Pays : Etats-Unis
Langue : ENG
Date de début :
Date de fin :
Spécialités : Hématologie
Peripheral blood CD26+ leukaemia stem cell monitoring in CML during TKI treatment
![Peripheral blood CD26+ leukaemia stem cell monitoring in CML during TKI treatment Peripheral blood CD26+ leukaemia stem cell monitoring in CML during TKI treatment](/images/videos/peripheral-blood-cd26-leukaemia-stem-cell-monitoring-in-cml-during-tki-treatment_20210622155119.png)
- Date : 08/12/2020
- 1
0
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL
![Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL](/images/videos/comparing-outcomes-of-first-line-ibrutinib-vs-chemoimmunotherapy-in-high-risk-cll_20210622155845.png)
- Date : 08/12/2020
- 0
0
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph+ ALL
![D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph+ ALL D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph+ ALL](/images/videos/d-alba-update-frontline-sequential-dasatinib-and-blinatumomab-in-adult-ph-all_20210622155700.png)
- Date : 08/12/2020
- 0
0
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation
![Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation](/images/videos/off-the-shelf-multi-virus-specific-t-cells-following-haematopoietic-stem-cell-transplantation_20210622155711.png)
- Date : 08/12/2020
- 0
0
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy
![Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy](/images/videos/weekly-carfilzomib-lenalidomide-dexamethasone-and-daratumumab-wkrd-d-combination-therapy_20210622155721.png)
- Date : 08/12/2020
- 0
0
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk
![ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk](/images/videos/ascent-a-phase-ii-trial-of-induction-consolidation-and-maintenance-in-subjects-with-high-risk_20210622155732.png)
- Date : 08/12/2020
- 0
0
Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML
![Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML](/images/videos/safety-and-efficacy-of-decitabine-plus-ipilimumab-in-relapsed-or-refractory-mds-aml_20210622155751.png)
- Date : 08/12/2020
- 0
0
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation
![First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation](/images/videos/first-in-class-stamp-inhibitor-asciminib-in-patients-with-cml-harbouring-the-t315i-mutation_20210622155803.png)
- Date : 08/12/2020
- 0
0
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia
![Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia](/images/videos/inotuzumab-ozogamicin-in-paediatric-cd22-positive-r-r-acute-lymphoblastic-leukaemia_20210622155824.png)
- Date : 08/12/2020
- 0
0
MURANO trial: Sustained disease survival in CLL following venetoclax plus rituximab
![MURANO trial: Sustained disease survival in CLL following venetoclax plus rituximab MURANO trial: Sustained disease survival in CLL following venetoclax plus rituximab](/images/videos/murano-trial-sustained-disease-survival-in-cll-following-venetoclax-plus-rituximab_20210622155906.png)
- Date : 08/12/2020
- 0
0
Researchers trace the origin of blood cancer to early childhood, decades before diagnosis
![Researchers trace the origin of blood cancer to early childhood, decades before diagnosis Researchers trace the origin of blood cancer to early childhood, decades before diagnosis](/images/videos/researchers-trace-the-origin-of-blood-cancer-to-early-childhood-decades-before-diagnosis_20210622155917.png)
- Date : 08/12/2020
- 0
0
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine
![ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine](/images/videos/etnk1-mutations-in-atypical-chronic-myeloid-leukaemia-can-be-reverted-with-phosphoethanolamine_20210622155927.png)
- Date : 08/12/2020
- 0
0
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and Bortezomib
![A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and Bortezomib A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and Bortezomib](/images/videos/a-treatment-comparison-of-carfilzomib-dexamethasone-and-daratumumab-to-daratumumab-and-bortezomib_20210622160053.png)
- Date : 08/12/2020
- 0
0
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients
![Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients](/images/videos/real-world-evidence-of-the-use-of-carfilzomib-to-refractory-to-lenalidomide-patients_20210622160226.png)
- Date : 08/12/2020
- 0
0
Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute
![Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute](/images/videos/long-term-follow-up-of-low-intensity-chemotherapy-with-combination-therapy-for-r-r-ph-acute_20210622160329.png)
- Date : 08/12/2020
- 0
0
Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients
![Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients](/images/videos/results-of-venetoclax-and-azacitidine-combination-in-chemotherapy-ineligible-untreated-patients_20210622160343.png)
- Date : 08/12/2020
- 0
0
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves
![Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves](/images/videos/cranial-radiation-mostly-eliminated-in-children-with-t-all-and-bortezomib-potentially-improves_20210622155407.png)
- Date : 08/12/2020
- 0
0
Clinical activity and safety of cevostamab in relapsed/refractory multiple myelomavvvv
![Clinical activity and safety of cevostamab in relapsed/refractory multiple myelomavvvv Clinical activity and safety of cevostamab in relapsed/refractory multiple myelomavvvv](/images/videos/clinical-activity-and-safety-of-cevostamab-in-relapsed-refractory-multiple-myelomavvvv_20210622155150.png)
- Date : 08/12/2020
- 0
0
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
![Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma](/images/videos/novel-bispecific-t-cell-engager-molecule-shows-promise-in-r-r-multiple-myeloma_20210622155201.png)
- Date : 08/12/2020
- 0
0
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the random
![Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the random Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the random](/images/videos/survival-analysis-of-newly-diagnosed-transplant-eligible-multiple-myeloma-patients-in-the-random_20210622155213.png)
- Date : 08/12/2020
- 0
0
FORTE Trial: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma
![FORTE Trial: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma FORTE Trial: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma](/images/videos/forte-trial-impact-of-imaging-fdg-pet-ct-minimal-residual-disease-assessment-on-multiple-myeloma_20210622155317.png)
- Date : 08/12/2020
- 0
0
B-HOLISTIC study and the importance of r/r Hodgkin lymphoma real world evidence data
![B-HOLISTIC study and the importance of r/r Hodgkin lymphoma real world evidence data B-HOLISTIC study and the importance of r/r Hodgkin lymphoma real world evidence data](/images/videos/b-holistic-study-and-the-importance-of-r-r-hodgkin-lymphoma-real-world-evidence-data_20210622155336.png)
- Date : 08/12/2020
- 0
0
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated
![Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated](/images/videos/evaluation-of-mrd-negativity-in-patients-with-relapsed-or-refractory-multiple-myeloma-treated_20210622155352.png)
- Date : 08/12/2020
- 0
0
Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukaemia
![Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukaemia Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukaemia](/images/videos/ibrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukaemia_20210622155431.png)
- Date : 08/12/2020
- 0
0
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
![Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma](/images/videos/neurocognitive-impairment-in-long-term-survivors-of-childhood-hodgkin-lymphoma_20210622155442.png)
- Date : 08/12/2020
- 0
0
Bosutinib versus imatinib for newly diagnosed chronic phase CML: Bfore trial final 5-year results
![Bosutinib versus imatinib for newly diagnosed chronic phase CML: Bfore trial final 5-year results Bosutinib versus imatinib for newly diagnosed chronic phase CML: Bfore trial final 5-year results](/images/videos/bosutinib-versus-imatinib-for-newly-diagnosed-chronic-phase-cml-bfore-trial-final-5-year-results_20210622155504.png)
- Date : 08/12/2020
- 0
0
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients
![Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients](/images/videos/weekly-carfilzomib-and-dexamethasone-plus-minus-cyclophosphamide-for-rrmm-patients_20210622155515.png)
- Date : 08/12/2020
- 0
0
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated
![Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated](/images/videos/clinical-implications-of-mrd-detection-in-infants-with-kmt2a-rearranged-all-treated_20210622155540.png)
- Date : 08/12/2020
- 0
0
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory
![Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory](/images/videos/ponatinib-venetoclax-and-dexamethasone-for-patients-with-relapsed-or-refractory_20210622155604.png)
- Date : 08/12/2020
- 0
0
Sélection de congrès
33ème Congrès International de la Society on Thrombosis and Haemostasis - ISTH 2025
- Date : 21/06/2025
-
472 0
Sommet Comprehensive Care de la Fédération Internationale de l'hémophilie – FMH 2025
![Sommet Comprehensive Care de la Fédération Internationale de l'hémophilie – FMH 2025](/images/conferences/sommet-comprehensive-care-de-la-f-d-ration-internationale-de-lh-mophilie-fmh-2025_medium.jpeg)
- Date : 23/04/2025
-
292 0